Engerix-B Vaccine Description
Engerix-B is a noninfectious recombinant DNA hepatitis B vaccine. It contains purified surface antigen of the virus obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus.
Engerix-B (Hep-B) is a noninfectious recombinant DNA vaccine containing hepatitis B surface antigen (HBsAg). It is produced from genetically engineered yeast (Saccharomyces cerevisiae). Intramuscular Hep-B [0-, 1-, 6-month schedule] has excellent immunogenicity in healthy neonates and infants, children, adolescents, and adults, with seroprotection rates of 85-100% seen approximate, equals 1 month after the final dose of vaccine; seroprotection was defined as an antibody against HBsAg (anti-HBs) titre of > or =10 IU/L.
Engerix-B is a trademark of the GlaxoSmithKline group of companies.
Engerix-B Vaccine Indication
Engerix-B is a vaccine for immunization against infection caused by all known subtypes of the hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination.
Engerix-B Vaccine Dosage
Engerix-B is administered as an intramuscular injection for persons aged 20 years and older consisting of a series of 3 doses given on a 0-, 1-, and 6-month schedule.
Primary immunization for infants (born of hepatitis B surface antigen [HBsAg]-negative or HBsAg-positive mothers), children (birth through 10 years), and adolescents (aged 11 through 19 years) consist of a series of 3 doses given on a 0-, 1-, and 6-month schedule.
Engerix-B Clinical Trials
GSK's Engerix-B has been studied in over 60 clinical trials.